Physician profile
Christopher W Wu
NPI 1952342305
$26,210.77
in general payments reported to CMS, 2019-2025
38 companies · $4,791 in 2025
The $4,791 reported for 2025 was more than what 85% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $2,324 · 2021: $2,025 · 2022: $344 · 2023: $490 · 2024: $1,051 · 2025: $4,791.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,680 · Food and Beverage: $2,328 · Travel and Lodging: $215 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,680.00 |
| Food and Beverage | $2,327.84 |
| Travel and Lodging | $215.46 |
| Education | $107.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $14,115.13 | 2019-2025 | |
| Horizon Therapeutics Plc | $4,604.61 | 2019-2020 | |
| Pfizer INC. | $2,114.92 | 2019-2024 | |
| Amgen INC. | $879.82 | 2019-2025 | Tavneos, Evenity, Amjevita |
| Ucb, INC. | $537.42 | 2019-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $405.54 | 2019-2025 | Tremfya, Simponi Aria |
| E.R. Squibb & Sons, L.L.C. | $377.70 | 2019-2025 | Orencia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $338.64 | 2019-2025 | Cyltezo, Ofev, Spevigo |
| Novartis Pharmaceuticals Corporation | $321.50 | 2019-2025 | |
| Lilly USA, LLC | $266.79 | 2019-2025 | Taltz |
| Janssen Scientific Affairs, LLC | $226.63 | 2019-2022 | |
| Celgene Corporation | $191.21 | 2019 | |
| Genentech USA, INC. | $181.41 | 2019-2025 | Gazyva |
| Mallinckrodt Enterprises LLC | $178.41 | 2019 | |
| Alexion Pharmaceuticals, INC. | $166.02 | 2019-2025 | Strensiq, Ultomiris |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.